Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

To Market Qsymia, Vivus Takes On Additional Debt

This article was originally published in The Pink Sheet Daily

Executive Summary

Sales of the weight-loss drug haven’t been brisk, but Vivus can fortify its balance sheet with up to $110 million in debt. Analysts say it could raise more soon, provided it gains a regulatory victory.

You may also be interested in...



Vivus’ Qsiva Down But Not Out At EMA; Lundbeck Will Write Off Acrescent

Vivus’ decision to fight CHMP rejection of Qsiva is a worthy cause, but Lundbeck confirms that Acrescent’s not unexpected elimination is the end of the line for the Alzheimer’s drug combination.

REMS For Qsymia Limits Distribution, But Vivus To Explore Expanding Access

Qsymia will launch through certified mail-order pharmacies, but FDA has asked the sponsor to look for ways to expand into the retail space with pharmacies that can meet requirements for distributing patient risk information and keeping track of prescribers.

FDA Approves Vivus’ Obesity Drug, Recommends Against Use In High-Risk Heart Patients

A Risk Evaluation and Mitigation Strategy for Qsymia includes prescriber education about the risk of birth defects and limits dispensing to specially certified pharmacies

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel